Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.

Publikation

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment.

Wissenschaftlicher Artikel/Review - 24.08.2022

Su E, Fischer Katharina S, R Demmer-Steingruber, Nigg Susanne, Güsewell Sabine, Albrich Werner, Rothermundt Christian, Silzle Tobias, Kahlert Christian

Zitation

Su E, Fischer K, R Demmer-Steingruber, Nigg S, Güsewell S, Albrich W, Rothermundt C, Silzle T, Kahlert C. Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment. ESMO Open 2022; 7:100587.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

ESMO Open 2022; 7

Veröffentlichungsdatum

24.08.2022

eISSN (Online)

2059-7029

Seiten

100587

Kurzbeschreibung/Zielsetzung

Patients with cancer are at high risk for severe coronavirus disease 2019 (COVID-19) infection. Knowledge regarding the efficacy of the messenger RNA (mRNA) vaccines in actively treated cancer patients is limited as they had been excluded from the pivotal studies of these vaccines. We evaluated humoral and cellular immune responses in cancer patients after double vaccination and a booster dose and identified disease- and treatment-related factors associated with a reduced immune response. We also documented the number and outcome of breakthrough infections.